ArticleBMC oral health2026
Ginsenoside Rg1 attenuates experimental periodontitis via modulating the PI3K/AKT pathway and TLR2 expression.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeriodontitis is a persistent inflammatory disease caused by the interplay between periodontal pathogens and the host immune response, leading not only to inflammatory infiltration of periodontal tissues but also to resorption and destruction of alveolar bone. Ginsenoside Rg1, a major pharmacologically active constituent of ginseng, exhibits anti-inflammatory, osteogenic, and immunomodulatory properties. This study investigated the therapeutic potential of Rg1 in an experimental periodontitis model in rats and explored its underlying molecular mechanisms.
methodsAn experimental periodontitis model was established in 8-week-old male Sprague-Dawley (SD) rats by ligating the maxillary first molars and inoculating with Porphyromonas gingivalis suspension. Micro-computed tomography (micro-CT) and hematoxylin–eosin (H&E) staining were used to evaluate inflammatory bone destruction. Tartrate-resistant acid phosphatase (TRAP) staining and immunofluorescence (IF) were performed to assess osteoclast numbers and osteogenic marker expression. Gene and protein expression levels of inflammatory cytokines and the immune receptor Toll-like receptor 2 (TLR2) were measured using RT-PCR and IF. Western blotting was conducted to evaluate the phosphorylation status of the PI3K/AKT signaling pathway.
resultsRg1 at a dose of 500 µg/kg exhibited optimal pharmacological activity, effectively alleviating inflammatory damage and bone destruction in periodontitis rats. Rg1 treatment significantly decreased the expression of TLR2 and IL-1β, while increasing that of TGF-β1. Additionally, Rg1 upregulated the expression of osteogenic markers and inhibited osteoclast formation. Notably, co-treatment with PI3K/AKT pathway inhibitor LY294002 significantly reduced the protective effects of Rg1, suggesting that the PI3K/AKT pathway is indispensable for its protective effects.
conclusionGinsenoside Rg1 attenuates experimental periodontitis by regulating the PI3K/AKT signaling pathway and suppressing TLR2 expression. This study provides a novel reference for pharmacological mechanism and new drug development of Rg1 in the therapeutic applications of periodontitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.